Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Spanish reimbursement system

- PMLiVE

MSD wins key EU approval for Keytruda, Alimta combo

Decision keeps Keytruda well ahead of rival Tecentriq

- PMLiVE

Stepping up for Leeds Mind

On 31st August 2018 the team at Mednet Group walked 27.5km across Yorkshire and raised £1,713.00 for local charity, Leeds Mind. A charity which promotes positive mental health and wellbeing...

Mednet

- PMLiVE

FDA rejects GSK’s Nucala for COPD

Says evidence that Nucala was effective in preventing COPD exacerbations was insufficient

- PMLiVE

NICE turns down Opdivo for adjuvant melanoma therapy

BMS drug currently only licensed treatment in this setting

AstraZeneca AZ

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

Clinical data from the TSLP targeting antibody is due in 2020

- PMLiVE

Outdated health service IT ‘cost lives’ says health secretary

Matt Hancock outlines plan for a “tech-driven” NHS

Gilead Sciences

Gilead, Galapagos JAK inhibitor clears phase II test

Hopes to compete with already-marketed drugs from Pfizer and Eli Lilly

HSJ Awards Finalists Announced

2018 HSJ Awards Finalists Announced.

Wilmington Healthcare

- PMLiVE

FDA gives Loxo breakthrough tag for second cancer drug

US regulatory body to expect a NDA for LOXO-292 in late 2019

- PMLiVE

Novartis sells off part of Sandoz portfolio

Swiss pharma giant will retain biosimilars

- PMLiVE

Sangamo’s first gene-editing trial doesn’t convince investors

Market spooked by inconclusive early results

- PMLiVE

Money, sex and power

What really makes your world go round? Is it money, sex or power? Or is it something more subtle?

Page & Page Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links